Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23328269

DOI

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Antineoplastic Combined Chemotherapy Protocols /adverse effects /economics /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy /economics /mortality /pathology; China; Cisplatin /administration & dosage /economics; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Delivery of Health Care /economics; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Glutamates /administration & dosage /economics; Guanine /administration & dosage /analogs & derivatives /economics; Humans; Lung Neoplasms /drug therapy /economics /mortality /pathology; Markov Chains; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome

AccessionNumber
22013006531

Date bibliographic record published
25/02/2013